Search

Wednesday 26 June 2024

CYP Phase 2 Trial approved

Cynata Therapeutics (ASX:CYP), a clinical-stage biotechnology company specialising in cell therapeutics, has received regulatory and ethics approval to commence its Phase 2 clinical trial at clinical centres in Turkey | ASX announcement: https://app.sharelinktechnologies.com/announcement/asx/e0fa6ac7f7a6ddf39eef8d4299365c12 #shorts

Free stock updates

Subscribe to receive the latest stock news, CEO interviews, expert insights, events and offers directly into your inbox